Akston Biosciences and Biolexis Collaborate to Launch a Room Temperature Stable 2nd Generation COVID-19 Vaccine in 130+ Countries
Biolexis has in-licensed AKS-452, a room temperature stable COVID-19 vaccine developed on Akston’s proprietary Fc fusion protein platform Biolexis will launch AKS-452 as "AmbiVax-CTM" for global mar...